Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. develops and manages licensed healthcare assets while advancing a pipeline of novel, multifunctional biotherapeutics for oncology. Company news centers on Ziihera (zanidatamab-hrii) and zanidatamab-related regulatory and clinical updates, including HER2-targeted development, as well as ZW191, a folate receptor alpha-targeting antibody-drug conjugate with Fast Track designation for advanced or metastatic platinum-resistant ovarian cancer.
Recurring updates also cover antibody-drug conjugate platform work, including RAS inhibitor ADC programs and targets such as CLDN18.2, Ly6E and PTK7, along with financial results, cash resources, share repurchase activity, investor conference participation and executive leadership appointments.
Zymeworks (Nasdaq: ZYME) authorized a 2026 share repurchase program to buy back up to $125 million of common stock. The company simultaneously ended its 2025 program, under which it spent $102.3 million at an average price of $24.36 per share.
As of May 13, 2026, Zymeworks had about 73.0 million shares outstanding. Repurchases may occur in the open market or via other methods and can be suspended or discontinued at any time.
Zymeworks (Nasdaq: ZYME) announced participation in several upcoming investor events focused on oncology and healthcare.
Management will join virtual and in-person fireside chats and one-on-one meetings at the 2026 Stifel Virtual Targeted Oncology Forum, TD Cowen 7th Annual Oncology Innovation Summit, and 2026 Jefferies Global Healthcare Conference.
Zymeworks (NASDAQ: ZYME) reported 1Q2026 results and a corporate update. Key items: FDA Priority Review with a PDUFA date of Aug 25, 2026 for zanidatamab in first-line HER2+ GEA; NMPA sBLA acceptance in China; and Breakthrough Therapy designation for the zanidatamab combination.
Clinical: ZW191 Part 1 showed a 56% confirmed ORR, 68% tumor regression, and 94% disease control; Part 2 fully enrolled (60 patients). Financials: $403.8M cash; $95.8M repurchased; 1Q revenue $2.4M; net loss $44.2M. Company reiterates ~$300M adjusted gross operating expense guidance over 2026–2028.
Zymeworks (Nasdaq: ZYME) on April 21, 2026 presented Phase 1 dose-escalation data for ZW191, an FRα-targeting ADC showing strong anti-tumor activity and manageable safety in heavily pretreated ovarian and endometrial cancers.
Key data: confirmed ORR up to 61% at 6.4–9.6 mg/kg, median progression-free survival 7.6 months, duration of response not reached, and tolerability to 11.2 mg/kg.
Zymeworks (Nasdaq: ZYME) announced six AACR 2026 presentations (one oral, April 21) covering preclinical ADC programs and new payload classes. Key highlights include a clinical-stage FRα ADC ZW191 (NCT06555744) with favorable tolerability signals and multiple pan-RASi ADCs showing strong tumor regressions at doses as low as 1 mg/kg in animal models.
Programs include PTK7 (ZW418), Ly6E (ZW427), CLDN18.2 (ZW439), a tricomplex pan-RASi ADC platform, and >40 novel eIF4A inhibitor payloads supporting broader ADC development.
Zymeworks (Nasdaq: ZYME) will report first quarter 2026 financial results after market close on May 7, 2026. Management will host a conference call and live webcast the same day at 4:30 PM ET to discuss results and provide a corporate update. Webcast replay and dial-in details will be available on the company website.
Zymeworks (Nasdaq: ZYME) announced full-time appointments of Dr. Adam Schayowitz as Executive VP & Head of R&D and Scott Platshon as Executive VP & Chief Business Officer, effective April 9, 2026.
Both report to CEO Kenneth Galbraith and will advance clinical programs, asset aggregation, and management of licensed assets including Ziihera and pasritamig. The company cited Phase 1 initiation for ZW251 and positive Phase 3 HERIZON-GEA-01 data for zanidatamab as momentum supporting its integrated R&D and partnership strategy.
Zymeworks (Nasdaq: ZYME) appointed Kristin Stafford as Chief Financial Officer, effective April 1, 2026. Ms. Stafford joins from Royalty Pharma with experience in strategic planning, capital markets, acquisitions and SEC reporting. She is a CPA, holds a B.Sc. in business administration and serves on the Novocure board.
This leadership hire aims to support disciplined capital allocation and execution of Zymeworks' strategic priorities.
Zymeworks (Nasdaq: ZYME) announced the U.S. FDA granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for advanced or metastatic platinum‑resistant ovarian cancer (PROC) on March 30, 2026.
ZW191 is in an ongoing Phase 1 study (NCT06555744) evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity; FRα is reported in ~75% of high‑grade serous ovarian carcinomas, >50% of endometrial cancers, and ~70% of lung adenocarcinomas.
Zymeworks (Nasdaq: ZYME) announced management will participate in two investor conferences in April 2026: Needham 25th Annual Virtual Healthcare Conference and Bloom Burton & Co. Healthcare Investor Conference.
Presentations: April 15, 2026 at 10:15 AM ET (virtual) and April 21, 2026 in Toronto, ON. According to the company, management will hold one-on-one meetings and investor presentations at both events.